Dave Denton: Chris, on the cost program, I would not read into the allocation of savings in 2023 as it relates to 2024. Obviously, we have a fairly robust program up and running today. We’re working aggressively on those programs and beginning to implement those programs. As we cycle into 2024, we’ll give you and the markets specific color on how to think about those cost savings as we wrap into next year.
Mark Southey: Angela?
Angela Hwang: We’re really pleased with our performance on ABRYSVO. It has exceeded our expectations. You first asked whether this is all about stocking. And I can say that it isn’t. Of course, there was stocking effect in the beginning because this was a new vaccine. But we’re also closely tracking vaccination rates and uptake. And what you see is that there is very fast uptake that really benefit from the fact that this was approved and in market prior to the vaccination season actually happening. So it was able to ride off the coattails of flu vaccinations, which you know are very high. Right? September, October. We have about a 70% co-administration rate. The performance we’re seeing on ABRYSVO is truly driven by vaccinations.
To your comment about market share, yes, we are seeing a similar market share to what you have just said. That is because, right now, the retail setting is driving a lot of the vaccinations. But don’t forget that that’s not where all vaccinations are taking place. We also have non-retail settings such as health systems, doctors’ offices, those are also being engaged. And those particular settings, Pfizer actually has a leading preference. They are smaller in proportion, but still. So I think we have to look at all channels of the market. Finally, I think that, just from a momentum perspective, we expect things to continue. The vaccinations really are happening throughout this time now – October, November, December are big vaccination months.
From where we are right now, RSV is only 5% of the entire vaccination rate of the eligible populations. So I think that the conclusion is we’re very early in the innings of this launch. It’s doing better than we thought. But where we are going to be, I think, is a place where there’s tremendous opportunity for driving uptake in older adults, but also maternal, which, as you know, we just got the approval for.
Operator: Next, we have Carter Gould with Barclays.
Carter Gould: Maybe if you go back to oral danu, when we do get the Phase 2 data, what should our expectation be around communicating plans for Phase 3, which I guess is just a quicker way of saying, what’s a reasonable expectation for how quickly you could turn around the Phase 2 and start a Phase 3 and how much work Pfizer has already done on that front? And then, maybe just coming out of ESMO, on the back of the EV-302 data and the response with Pfizer saying that reaffirms their expectations or represents upside to their expectations when the deal was originally announced.
Albert Bourla: On the danu, let me take it, so I can spare a little bit Mikael’s time. We are expecting the data to show up before the end of the year. And of course, it’s an important event. So we will have to make it publicly known when we know the data. And of course, when we are ready with our Phase 3, and we hope that the data are good, so that we can move into Phase 3. And I hope that we are going to do it in an expedient manner because speed is of essence in this battle between competing molecules. But we will announce our plans for Phase 3. I know the interest is very high right now. But I want to be very prudent in not saying things without the data. The data or the click of the data, we haven’t seen it again. Now, let me move to Chris, so that we can discuss about the ESMO.
Chris Boshoff: Thank you for raising 301. It’s a truly monumental data for the field of bladder cancer, and urothelial cancer. And as you pointed out, with overall survival and median –progression-free survival nearly double, moving median overall survival for this population now nearly towards three years, we expect the final data to be above – longer than 31.5 months. So this just reaffirms our belief that antibody drug conjugates could become a standard of care across the treatment paradigm for many, many different tumor types.
Operator: Next, we have Akash Tewari with Jefferies.
Ivy Wang: This is Ivy on for Akash. Our question is also on danuglipron. So, [indiscernible] release version, is there any possibility to do a bridging study for QD formulation? And also, for danu, I think as we’ve heard a lot of times on the call that the trial [indiscernible] completed in October. I know you haven’t seen the top line data. So at this point, are we waiting for data from this lower four week titration cohort? So would it be fair to say that you will have to continue the program already if there were any clinically significant theories, issues with danu?
Mikael Dolsten: On the once a day reformulated danu, we have initially tested a standard swellable core technology, and could show that it worked very well with danu. Now to be able also to incorporate a more sophisticated technology, we worked on a matrix technology, and all data suggests it’s going to a really intriguing alternative because, as you know, in diabetes oral drugs and obesity, you will over time end up with incorporating different trials to prevent different downstream effects. And that’s the beautiful of having these type of novel technology that you have a potential in the future to go to fix those combination. And we are really masters in developing sophisticated formulations and we will have this available in 2024.
Mark Southey: And there was a second part I think, or not. There was a second part on danu?
Operator: Next we have Kerry Holford with Berenberg.
Kerry Holford: Two questions on vaccines for me, please. First on RSV, in August, GSK filed a lawsuit against Pfizer alleging patent infringement. So I wonder if you could just talk to the next steps here. Perhaps a timeline that you anticipate for this? And should we think that this could ultimately result in some form of royalty payments from Pfizer to GSK? And then, on PENBRAYA, how does the recent ACIP recommendation set against your expectations for the sales ramp and peak potential for this vaccine? If the vaccine is effectively only used for dose two of three, does that significantly reduce the commercial opportunity you had anticipated for the vaccine?
Doug Lankler: It’s very, very early stages with respect to the RSV litigation. We have patents, we feel strongly about our own intellectual property. And it’s certainly too early to say whether one party or the other will be required to pay any royalties or otherwise. Very early stages in that regard.
